CASI Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)
CASI Pharmaceuticals | EFFECT: Others
CASI Pharmaceuticals | F-3: Registration statement for specified transactions by certain foreign private issuers
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)
CASI Pharmaceuticals | 20-F: Registration statement / Annual report / Transition report
CASI Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-James Huang(19.99%),Panacea Venture Healthcare Fund II, L.P.(19.31%), etc.
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)
CASI Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-James Huang(18.0%),Panacea Venture Healthcare Fund II, L.P.(17.4%), etc.
CASI Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CASI Pharmaceuticals | UPLOAD: Others
CASI Pharmaceuticals | CORRESP: CORRESP
No Data